MovDisordV3, PascalFrancis, Corpus, bibRecord, 001520

Aripiprazole : A Treatment for Severe Coprolalia in "Refractory" Gilles de la Tourette Syndrome

Identifieur interne : 001520 ( PascalFrancis/Corpus ); précédent : 001519; suivant : 001521

Aripiprazole : A Treatment for Severe Coprolalia in "Refractory" Gilles de la Tourette Syndrome

Auteurs : Mouna Ben Djebara ; Yulia Worbe ; Michael Schupbach ; Andreas Hartmann

Source :

Movement disorders [ 0885-3185 ] ; 2008.

RBID : Francis:08-0169590

Descripteurs français

Pascal (Inist)
- Syndrome de Gilles de la Tourette, Pathologie du système nerveux, Aripiprazole, Coprolalie.

English descriptors

KwdEn :
- Aripiprazole, Coprolalia, Gilles de la Tourette syndrome, Nervous system diseases.

Abstract

Coprolalia is one of the most distressing symptoms in Gilles de la Tourette syndrome. We report on a 28-year-old man with severe coprolalia at the forefront of symptoms, which had a dramatic impact on his social and professional life and that did not fluctuate for years. Moreover, he presented hypersensitivity to neuroleptics. The use of aripiprazole, as a last resort, induced a 75% of improvement of his symptoms with good tolerance. This suggests that aripiprazole constitutes a valuable therapeutic in coprolalia. Moreover, its biochemical class specificity makes it an alternative for patients hypersensitive to other classes of neuroleptics.

Notice en format standard (ISO 2709)

Pour connaître la documentation sur le format Inist Standard.

A01	`01`	`1`		`@0 0885-3185`
A03		`1`		`@0 Mov. disord.`
A05				`@2 23`
A06				`@2 3`
A08	`01`	`1`	`FRE`	`@1 Aripiprazole : A Treatment for Severe Coprolalia in "Refractory" Gilles de la Tourette Syndrome`
A11	`01`	`1`		`@1 BEN DJEBARA (Mouna)`
A11	`02`	`1`		`@1 WORBE (Yulia)`
A11	`03`	`1`		`@1 SCHUPBACH (Michael)`
A11	`04`	`1`		`@1 HARTMANN (Andreas)`
A14	`01`			`@1 Centre d'Investigation Clinique, Fédération de Neurologie @2 Paris @3 FRA @Z 1 aut. @Z 2 aut. @Z 3 aut. @Z 4 aut.`
A14	`02`			`@1 INSERM, UMR 679, Neurology and Expérimental Therapeutics @2 Paris @3 FRA @Z 1 aut. @Z 2 aut. @Z 3 aut. @Z 4 aut.`
A14	`03`			`@1 AP-HP, Pitié-Salpêtrière Group, Fédération de Neurologie @2 Paris @3 FRA @Z 1 aut. @Z 2 aut. @Z 3 aut. @Z 4 aut.`
A14	`04`			`@1 Faculté de Médecine, Université Pierre et Marie Curie @2 Paris @3 FRA @Z 1 aut. @Z 2 aut. @Z 3 aut. @Z 4 aut.`
A20				`@1 438-440`
A21				`@1 2008`
A23	`01`			`@0 FRE`
A24	`01`			`@0 eng`
A43	`01`			`@1 INIST @2 20953 @5 354000173639210190`
A44				`@0 0000 @1 © 2008 INIST-CNRS. All rights reserved.`
A45				`@0 15 ref.`
A47	`01`	`1`		`@0 08-0169590`
A60				`@1 P @3 CC`
A61				`@0 A`
A64	`01`	`1`		`@0 Movement disorders`
A66	`01`			`@0 USA`
C01	`01`		`ENG`	@0 Coprolalia is one of the most distressing symptoms in Gilles de la Tourette syndrome. We report on a 28-year-old man with severe coprolalia at the forefront of symptoms, which had a dramatic impact on his social and professional life and that did not fluctuate for years. Moreover, he presented hypersensitivity to neuroleptics. The use of aripiprazole, as a last resort, induced a 75% of improvement of his symptoms with good tolerance. This suggests that aripiprazole constitutes a valuable therapeutic in coprolalia. Moreover, its biochemical class specificity makes it an alternative for patients hypersensitive to other classes of neuroleptics.
C02	`01`	`X`		`@0 770E02 @1 V`
C03	`01`	`X`	`FRE`	`@0 Syndrome de Gilles de la Tourette @5 01`
C03	`01`	`X`	`ENG`	`@0 Gilles de la Tourette syndrome @5 01`
C03	`01`	`X`	`SPA`	`@0 Gilles de la Tourette síndrome @5 01`
C03	`02`	`X`	`FRE`	`@0 Pathologie du système nerveux @5 02`
C03	`02`	`X`	`ENG`	`@0 Nervous system diseases @5 02`
C03	`02`	`X`	`SPA`	`@0 Sistema nervioso patología @5 02`
C03	`03`	`X`	`FRE`	`@0 Aripiprazole @2 NK @2 FR @5 09`
C03	`03`	`X`	`ENG`	`@0 Aripiprazole @2 NK @2 FR @5 09`
C03	`03`	`X`	`SPA`	`@0 Aripiprazol @2 NK @2 FR @5 09`
C03	`04`	`X`	`FRE`	`@0 Coprolalie @5 10`
C03	`04`	`X`	`ENG`	`@0 Coprolalia @5 10`
C03	`04`	`X`	`SPA`	`@0 Coprolalia @5 10`
C07	`01`	`X`	`FRE`	`@0 Pathologie de l'encéphale @5 37`
C07	`01`	`X`	`ENG`	`@0 Cerebral disorder @5 37`
C07	`01`	`X`	`SPA`	`@0 Encéfalo patología @5 37`
C07	`02`	`X`	`FRE`	`@0 Maladie dégénérative @5 38`
C07	`02`	`X`	`ENG`	`@0 Degenerative disease @5 38`
C07	`02`	`X`	`SPA`	`@0 Enfermedad degenerativa @5 38`
C07	`03`	`X`	`FRE`	`@0 Pathologie du système nerveux central @5 39`
C07	`03`	`X`	`ENG`	`@0 Central nervous system disease @5 39`
C07	`03`	`X`	`SPA`	`@0 Sistema nervosio central patología @5 39`
N21				`@1 105`
N44	`01`			`@1 OTO`
N82				`@1 OTO`

Format Inist (serveur)

NO :	FRANCIS 08-0169590 INIST
FT :	Aripiprazole : A Treatment for Severe Coprolalia in "Refractory" Gilles de la Tourette Syndrome
AU :	BEN DJEBARA (Mouna); WORBE (Yulia); SCHUPBACH (Michael); HARTMANN (Andreas)
AF :	Centre d'Investigation Clinique, Fédération de Neurologie/Paris/France (1 aut., 2 aut., 3 aut., 4 aut.); INSERM, UMR 679, Neurology and Expérimental Therapeutics/Paris/France (1 aut., 2 aut., 3 aut., 4 aut.); AP-HP, Pitié-Salpêtrière Group, Fédération de Neurologie/Paris/France (1 aut., 2 aut., 3 aut., 4 aut.); Faculté de Médecine, Université Pierre et Marie Curie/Paris/France (1 aut., 2 aut., 3 aut., 4 aut.)
DT :	Publication en série; Courte communication, note brève; Niveau analytique
SO :	Movement disorders; ISSN 0885-3185; Etats-Unis; Da. 2008; Vol. 23; No. 3; Pp. 438-440; Abs. anglais; Bibl. 15 ref.
LA :	Français
EA :	Coprolalia is one of the most distressing symptoms in Gilles de la Tourette syndrome. We report on a 28-year-old man with severe coprolalia at the forefront of symptoms, which had a dramatic impact on his social and professional life and that did not fluctuate for years. Moreover, he presented hypersensitivity to neuroleptics. The use of aripiprazole, as a last resort, induced a 75% of improvement of his symptoms with good tolerance. This suggests that aripiprazole constitutes a valuable therapeutic in coprolalia. Moreover, its biochemical class specificity makes it an alternative for patients hypersensitive to other classes of neuroleptics.
CC :	770E02
FD :	Syndrome de Gilles de la Tourette; Pathologie du système nerveux; Aripiprazole; Coprolalie
FG :	Pathologie de l'encéphale; Maladie dégénérative; Pathologie du système nerveux central
ED :	Gilles de la Tourette syndrome; Nervous system diseases; Aripiprazole; Coprolalia
EG :	Cerebral disorder; Degenerative disease; Central nervous system disease
SD :	Gilles de la Tourette síndrome; Sistema nervioso patología; Aripiprazol; Coprolalia
LO :	INIST-20953.354000173639210190
ID :	08-0169590

Links to Exploration step

Francis:08-0169590

Le document en format XML

<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="fr" level="a">Aripiprazole : A Treatment for Severe Coprolalia in "Refractory" Gilles de la Tourette Syndrome</title>
<author><name sortKey="Ben Djebara, Mouna" sort="Ben Djebara, Mouna" uniqKey="Ben Djebara M" first="Mouna" last="Ben Djebara">Mouna Ben Djebara</name>
<affiliation><inist:fA14 i1="01"><s1>Centre d'Investigation Clinique, Fédération de Neurologie</s1>
<s2>Paris</s2>
<s3>FRA</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>4 aut.</sZ>
</inist:fA14>
</affiliation>
<affiliation><inist:fA14 i1="02"><s1>INSERM, UMR 679, Neurology and Expérimental Therapeutics</s1>
<s2>Paris</s2>
<s3>FRA</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>4 aut.</sZ>
</inist:fA14>
</affiliation>
<affiliation><inist:fA14 i1="03"><s1>AP-HP, Pitié-Salpêtrière Group, Fédération de Neurologie</s1>
<s2>Paris</s2>
<s3>FRA</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>4 aut.</sZ>
</inist:fA14>
</affiliation>
<affiliation><inist:fA14 i1="04"><s1>Faculté de Médecine, Université Pierre et Marie Curie</s1>
<s2>Paris</s2>
<s3>FRA</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>4 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Worbe, Yulia" sort="Worbe, Yulia" uniqKey="Worbe Y" first="Yulia" last="Worbe">Yulia Worbe</name>
<affiliation><inist:fA14 i1="01"><s1>Centre d'Investigation Clinique, Fédération de Neurologie</s1>
<s2>Paris</s2>
<s3>FRA</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>4 aut.</sZ>
</inist:fA14>
</affiliation>
<affiliation><inist:fA14 i1="02"><s1>INSERM, UMR 679, Neurology and Expérimental Therapeutics</s1>
<s2>Paris</s2>
<s3>FRA</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>4 aut.</sZ>
</inist:fA14>
</affiliation>
<affiliation><inist:fA14 i1="03"><s1>AP-HP, Pitié-Salpêtrière Group, Fédération de Neurologie</s1>
<s2>Paris</s2>
<s3>FRA</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>4 aut.</sZ>
</inist:fA14>
</affiliation>
<affiliation><inist:fA14 i1="04"><s1>Faculté de Médecine, Université Pierre et Marie Curie</s1>
<s2>Paris</s2>
<s3>FRA</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>4 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Schupbach, Michael" sort="Schupbach, Michael" uniqKey="Schupbach M" first="Michael" last="Schupbach">Michael Schupbach</name>
<affiliation><inist:fA14 i1="01"><s1>Centre d'Investigation Clinique, Fédération de Neurologie</s1>
<s2>Paris</s2>
<s3>FRA</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>4 aut.</sZ>
</inist:fA14>
</affiliation>
<affiliation><inist:fA14 i1="02"><s1>INSERM, UMR 679, Neurology and Expérimental Therapeutics</s1>
<s2>Paris</s2>
<s3>FRA</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>4 aut.</sZ>
</inist:fA14>
</affiliation>
<affiliation><inist:fA14 i1="03"><s1>AP-HP, Pitié-Salpêtrière Group, Fédération de Neurologie</s1>
<s2>Paris</s2>
<s3>FRA</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>4 aut.</sZ>
</inist:fA14>
</affiliation>
<affiliation><inist:fA14 i1="04"><s1>Faculté de Médecine, Université Pierre et Marie Curie</s1>
<s2>Paris</s2>
<s3>FRA</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>4 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Hartmann, Andreas" sort="Hartmann, Andreas" uniqKey="Hartmann A" first="Andreas" last="Hartmann">Andreas Hartmann</name>
<affiliation><inist:fA14 i1="01"><s1>Centre d'Investigation Clinique, Fédération de Neurologie</s1>
<s2>Paris</s2>
<s3>FRA</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>4 aut.</sZ>
</inist:fA14>
</affiliation>
<affiliation><inist:fA14 i1="02"><s1>INSERM, UMR 679, Neurology and Expérimental Therapeutics</s1>
<s2>Paris</s2>
<s3>FRA</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>4 aut.</sZ>
</inist:fA14>
</affiliation>
<affiliation><inist:fA14 i1="03"><s1>AP-HP, Pitié-Salpêtrière Group, Fédération de Neurologie</s1>
<s2>Paris</s2>
<s3>FRA</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>4 aut.</sZ>
</inist:fA14>
</affiliation>
<affiliation><inist:fA14 i1="04"><s1>Faculté de Médecine, Université Pierre et Marie Curie</s1>
<s2>Paris</s2>
<s3>FRA</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>4 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
</titleStmt>
<publicationStmt><idno type="wicri:source">INIST</idno>
<idno type="inist">08-0169590</idno>
<date when="2008">2008</date>
<idno type="stanalyst">FRANCIS 08-0169590 INIST</idno>
<idno type="RBID">Francis:08-0169590</idno>
<idno type="wicri:Area/PascalFrancis/Corpus">001520</idno>
</publicationStmt>
<sourceDesc><biblStruct><analytic><title xml:lang="fr" level="a">Aripiprazole : A Treatment for Severe Coprolalia in "Refractory" Gilles de la Tourette Syndrome</title>
<author><name sortKey="Ben Djebara, Mouna" sort="Ben Djebara, Mouna" uniqKey="Ben Djebara M" first="Mouna" last="Ben Djebara">Mouna Ben Djebara</name>
<affiliation><inist:fA14 i1="01"><s1>Centre d'Investigation Clinique, Fédération de Neurologie</s1>
<s2>Paris</s2>
<s3>FRA</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>4 aut.</sZ>
</inist:fA14>
</affiliation>
<affiliation><inist:fA14 i1="02"><s1>INSERM, UMR 679, Neurology and Expérimental Therapeutics</s1>
<s2>Paris</s2>
<s3>FRA</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>4 aut.</sZ>
</inist:fA14>
</affiliation>
<affiliation><inist:fA14 i1="03"><s1>AP-HP, Pitié-Salpêtrière Group, Fédération de Neurologie</s1>
<s2>Paris</s2>
<s3>FRA</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>4 aut.</sZ>
</inist:fA14>
</affiliation>
<affiliation><inist:fA14 i1="04"><s1>Faculté de Médecine, Université Pierre et Marie Curie</s1>
<s2>Paris</s2>
<s3>FRA</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>4 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Worbe, Yulia" sort="Worbe, Yulia" uniqKey="Worbe Y" first="Yulia" last="Worbe">Yulia Worbe</name>
<affiliation><inist:fA14 i1="01"><s1>Centre d'Investigation Clinique, Fédération de Neurologie</s1>
<s2>Paris</s2>
<s3>FRA</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>4 aut.</sZ>
</inist:fA14>
</affiliation>
<affiliation><inist:fA14 i1="02"><s1>INSERM, UMR 679, Neurology and Expérimental Therapeutics</s1>
<s2>Paris</s2>
<s3>FRA</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>4 aut.</sZ>
</inist:fA14>
</affiliation>
<affiliation><inist:fA14 i1="03"><s1>AP-HP, Pitié-Salpêtrière Group, Fédération de Neurologie</s1>
<s2>Paris</s2>
<s3>FRA</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>4 aut.</sZ>
</inist:fA14>
</affiliation>
<affiliation><inist:fA14 i1="04"><s1>Faculté de Médecine, Université Pierre et Marie Curie</s1>
<s2>Paris</s2>
<s3>FRA</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>4 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Schupbach, Michael" sort="Schupbach, Michael" uniqKey="Schupbach M" first="Michael" last="Schupbach">Michael Schupbach</name>
<affiliation><inist:fA14 i1="01"><s1>Centre d'Investigation Clinique, Fédération de Neurologie</s1>
<s2>Paris</s2>
<s3>FRA</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>4 aut.</sZ>
</inist:fA14>
</affiliation>
<affiliation><inist:fA14 i1="02"><s1>INSERM, UMR 679, Neurology and Expérimental Therapeutics</s1>
<s2>Paris</s2>
<s3>FRA</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>4 aut.</sZ>
</inist:fA14>
</affiliation>
<affiliation><inist:fA14 i1="03"><s1>AP-HP, Pitié-Salpêtrière Group, Fédération de Neurologie</s1>
<s2>Paris</s2>
<s3>FRA</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>4 aut.</sZ>
</inist:fA14>
</affiliation>
<affiliation><inist:fA14 i1="04"><s1>Faculté de Médecine, Université Pierre et Marie Curie</s1>
<s2>Paris</s2>
<s3>FRA</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>4 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Hartmann, Andreas" sort="Hartmann, Andreas" uniqKey="Hartmann A" first="Andreas" last="Hartmann">Andreas Hartmann</name>
<affiliation><inist:fA14 i1="01"><s1>Centre d'Investigation Clinique, Fédération de Neurologie</s1>
<s2>Paris</s2>
<s3>FRA</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>4 aut.</sZ>
</inist:fA14>
</affiliation>
<affiliation><inist:fA14 i1="02"><s1>INSERM, UMR 679, Neurology and Expérimental Therapeutics</s1>
<s2>Paris</s2>
<s3>FRA</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>4 aut.</sZ>
</inist:fA14>
</affiliation>
<affiliation><inist:fA14 i1="03"><s1>AP-HP, Pitié-Salpêtrière Group, Fédération de Neurologie</s1>
<s2>Paris</s2>
<s3>FRA</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>4 aut.</sZ>
</inist:fA14>
</affiliation>
<affiliation><inist:fA14 i1="04"><s1>Faculté de Médecine, Université Pierre et Marie Curie</s1>
<s2>Paris</s2>
<s3>FRA</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>4 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
</analytic>
<series><title level="j" type="main">Movement disorders</title>
<title level="j" type="abbreviated">Mov. disord.</title>
<idno type="ISSN">0885-3185</idno>
<imprint><date when="2008">2008</date>
</imprint>
</series>
</biblStruct>
</sourceDesc>
<seriesStmt><title level="j" type="main">Movement disorders</title>
<title level="j" type="abbreviated">Mov. disord.</title>
<idno type="ISSN">0885-3185</idno>
</seriesStmt>
</fileDesc>
<profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Aripiprazole</term>
<term>Coprolalia</term>
<term>Gilles de la Tourette syndrome</term>
<term>Nervous system diseases</term>
</keywords>
<keywords scheme="Pascal" xml:lang="fr"><term>Syndrome de Gilles de la Tourette</term>
<term>Pathologie du   système nerveux</term>
<term>Aripiprazole</term>
<term>Coprolalie</term>
</keywords>
</textClass>
</profileDesc>
</teiHeader>
<front><div type="abstract" xml:lang="en">Coprolalia is one of the most distressing symptoms in Gilles de la Tourette syndrome. We report on a 28-year-old man with severe coprolalia at the forefront of symptoms, which had a dramatic impact on his social and professional life and that did not fluctuate for years. Moreover, he presented hypersensitivity to neuroleptics. The use of aripiprazole, as a last resort, induced a 75% of improvement of his symptoms with good tolerance. This suggests that aripiprazole constitutes a valuable therapeutic in coprolalia. Moreover, its biochemical class specificity makes it an alternative for patients hypersensitive to other classes of neuroleptics.</div>
</front>
</TEI>
<inist><standard h6="B"><pA><fA01 i1="01" i2="1"><s0>0885-3185</s0>
</fA01>
<fA03 i2="1"><s0>Mov. disord.</s0>
</fA03>
<fA05><s2>23</s2>
</fA05>
<fA06><s2>3</s2>
</fA06>
<fA08 i1="01" i2="1" l="FRE"><s1>Aripiprazole : A Treatment for Severe Coprolalia in "Refractory" Gilles de la Tourette Syndrome</s1>
</fA08>
<fA11 i1="01" i2="1"><s1>BEN DJEBARA (Mouna)</s1>
</fA11>
<fA11 i1="02" i2="1"><s1>WORBE (Yulia)</s1>
</fA11>
<fA11 i1="03" i2="1"><s1>SCHUPBACH (Michael)</s1>
</fA11>
<fA11 i1="04" i2="1"><s1>HARTMANN (Andreas)</s1>
</fA11>
<fA14 i1="01"><s1>Centre d'Investigation Clinique, Fédération de Neurologie</s1>
<s2>Paris</s2>
<s3>FRA</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>4 aut.</sZ>
</fA14>
<fA14 i1="02"><s1>INSERM, UMR 679, Neurology and Expérimental Therapeutics</s1>
<s2>Paris</s2>
<s3>FRA</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>4 aut.</sZ>
</fA14>
<fA14 i1="03"><s1>AP-HP, Pitié-Salpêtrière Group, Fédération de Neurologie</s1>
<s2>Paris</s2>
<s3>FRA</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>4 aut.</sZ>
</fA14>
<fA14 i1="04"><s1>Faculté de Médecine, Université Pierre et Marie Curie</s1>
<s2>Paris</s2>
<s3>FRA</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>4 aut.</sZ>
</fA14>
<fA20><s1>438-440</s1>
</fA20>
<fA21><s1>2008</s1>
</fA21>
<fA23 i1="01"><s0>FRE</s0>
</fA23>
<fA24 i1="01"><s0>eng</s0>
</fA24>
<fA43 i1="01"><s1>INIST</s1>
<s2>20953</s2>
<s5>354000173639210190</s5>
</fA43>
<fA44><s0>0000</s0>
<s1>© 2008 INIST-CNRS. All rights reserved.</s1>
</fA44>
<fA45><s0>15 ref.</s0>
</fA45>
<fA47 i1="01" i2="1"><s0>08-0169590</s0>
</fA47>
<fA60><s1>P</s1>
<s3>CC</s3>
</fA60>
<fA61><s0>A</s0>
</fA61>
<fA64 i1="01" i2="1"><s0>Movement disorders</s0>
</fA64>
<fA66 i1="01"><s0>USA</s0>
</fA66>
<fC01 i1="01" l="ENG"><s0>Coprolalia is one of the most distressing symptoms in Gilles de la Tourette syndrome. We report on a 28-year-old man with severe coprolalia at the forefront of symptoms, which had a dramatic impact on his social and professional life and that did not fluctuate for years. Moreover, he presented hypersensitivity to neuroleptics. The use of aripiprazole, as a last resort, induced a 75% of improvement of his symptoms with good tolerance. This suggests that aripiprazole constitutes a valuable therapeutic in coprolalia. Moreover, its biochemical class specificity makes it an alternative for patients hypersensitive to other classes of neuroleptics.</s0>
</fC01>
<fC02 i1="01" i2="X"><s0>770E02</s0>
<s1>V</s1>
</fC02>
<fC03 i1="01" i2="X" l="FRE"><s0>Syndrome de Gilles de la Tourette</s0>
<s5>01</s5>
</fC03>
<fC03 i1="01" i2="X" l="ENG"><s0>Gilles de la Tourette syndrome</s0>
<s5>01</s5>
</fC03>
<fC03 i1="01" i2="X" l="SPA"><s0>Gilles de la Tourette síndrome</s0>
<s5>01</s5>
</fC03>
<fC03 i1="02" i2="X" l="FRE"><s0>Pathologie du   système nerveux</s0>
<s5>02</s5>
</fC03>
<fC03 i1="02" i2="X" l="ENG"><s0>Nervous system diseases</s0>
<s5>02</s5>
</fC03>
<fC03 i1="02" i2="X" l="SPA"><s0>Sistema nervioso patología</s0>
<s5>02</s5>
</fC03>
<fC03 i1="03" i2="X" l="FRE"><s0>Aripiprazole</s0>
<s2>NK</s2>
<s2>FR</s2>
<s5>09</s5>
</fC03>
<fC03 i1="03" i2="X" l="ENG"><s0>Aripiprazole</s0>
<s2>NK</s2>
<s2>FR</s2>
<s5>09</s5>
</fC03>
<fC03 i1="03" i2="X" l="SPA"><s0>Aripiprazol</s0>
<s2>NK</s2>
<s2>FR</s2>
<s5>09</s5>
</fC03>
<fC03 i1="04" i2="X" l="FRE"><s0>Coprolalie</s0>
<s5>10</s5>
</fC03>
<fC03 i1="04" i2="X" l="ENG"><s0>Coprolalia</s0>
<s5>10</s5>
</fC03>
<fC03 i1="04" i2="X" l="SPA"><s0>Coprolalia</s0>
<s5>10</s5>
</fC03>
<fC07 i1="01" i2="X" l="FRE"><s0>Pathologie de l'encéphale</s0>
<s5>37</s5>
</fC07>
<fC07 i1="01" i2="X" l="ENG"><s0>Cerebral disorder</s0>
<s5>37</s5>
</fC07>
<fC07 i1="01" i2="X" l="SPA"><s0>Encéfalo patología</s0>
<s5>37</s5>
</fC07>
<fC07 i1="02" i2="X" l="FRE"><s0>Maladie dégénérative</s0>
<s5>38</s5>
</fC07>
<fC07 i1="02" i2="X" l="ENG"><s0>Degenerative disease</s0>
<s5>38</s5>
</fC07>
<fC07 i1="02" i2="X" l="SPA"><s0>Enfermedad degenerativa</s0>
<s5>38</s5>
</fC07>
<fC07 i1="03" i2="X" l="FRE"><s0>Pathologie du   système nerveux central</s0>
<s5>39</s5>
</fC07>
<fC07 i1="03" i2="X" l="ENG"><s0>Central nervous system disease</s0>
<s5>39</s5>
</fC07>
<fC07 i1="03" i2="X" l="SPA"><s0>Sistema nervosio central patología</s0>
<s5>39</s5>
</fC07>
<fN21><s1>105</s1>
</fN21>
<fN44 i1="01"><s1>OTO</s1>
</fN44>
<fN82><s1>OTO</s1>
</fN82>
</pA>
</standard>
<server><NO>FRANCIS 08-0169590 INIST</NO>
<FT>Aripiprazole : A Treatment for Severe Coprolalia in "Refractory" Gilles de la Tourette Syndrome</FT>
<AU>BEN DJEBARA (Mouna); WORBE (Yulia); SCHUPBACH (Michael); HARTMANN (Andreas)</AU>
<AF>Centre d'Investigation Clinique, Fédération de Neurologie/Paris/France (1 aut., 2 aut., 3 aut., 4 aut.); INSERM, UMR 679, Neurology and Expérimental Therapeutics/Paris/France (1 aut., 2 aut., 3 aut., 4 aut.); AP-HP, Pitié-Salpêtrière Group, Fédération de Neurologie/Paris/France (1 aut., 2 aut., 3 aut., 4 aut.); Faculté de Médecine, Université Pierre et Marie Curie/Paris/France (1 aut., 2 aut., 3 aut., 4 aut.)</AF>
<DT>Publication en série; Courte communication, note brève; Niveau analytique</DT>
<SO>Movement disorders; ISSN 0885-3185; Etats-Unis; Da. 2008; Vol. 23; No. 3; Pp. 438-440; Abs. anglais; Bibl. 15 ref.</SO>
<LA>Français</LA>
<EA>Coprolalia is one of the most distressing symptoms in Gilles de la Tourette syndrome. We report on a 28-year-old man with severe coprolalia at the forefront of symptoms, which had a dramatic impact on his social and professional life and that did not fluctuate for years. Moreover, he presented hypersensitivity to neuroleptics. The use of aripiprazole, as a last resort, induced a 75% of improvement of his symptoms with good tolerance. This suggests that aripiprazole constitutes a valuable therapeutic in coprolalia. Moreover, its biochemical class specificity makes it an alternative for patients hypersensitive to other classes of neuroleptics.</EA>
<CC>770E02</CC>
<FD>Syndrome de Gilles de la Tourette; Pathologie du   système nerveux; Aripiprazole; Coprolalie</FD>
<FG>Pathologie de l'encéphale; Maladie dégénérative; Pathologie du   système nerveux central</FG>
<ED>Gilles de la Tourette syndrome; Nervous system diseases; Aripiprazole; Coprolalia</ED>
<EG>Cerebral disorder; Degenerative disease; Central nervous system disease</EG>
<SD>Gilles de la Tourette síndrome; Sistema nervioso patología; Aripiprazol; Coprolalia</SD>
<LO>INIST-20953.354000173639210190</LO>
<ID>08-0169590</ID>
</server>
</inist>
</record>

Pour manipuler ce document sous Unix (Dilib)

EXPLOR_STEP=$WICRI_ROOT/Wicri/Santé/explor/MovDisordV3/Data/PascalFrancis/Corpus

HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 001520 | SxmlIndent | more

HfdSelect -h $EXPLOR_AREA/Data/PascalFrancis/Corpus/biblio.hfd -nk 001520 | SxmlIndent | more

Pour mettre un lien sur cette page dans le réseau Wicri

{{Explor lien
   |wiki=    Wicri/Santé
   |area=    MovDisordV3
   |flux=    PascalFrancis
   |étape=   Corpus
   |type=    RBID
   |clé=     Francis:08-0169590
   |texte=   Aripiprazole : A Treatment for Severe Coprolalia in "Refractory" Gilles de la Tourette Syndrome
}}

This area was generated with Dilib version V0.6.23.
Data generation: Sun Jul 3 12:29:32 2016. Site generation: Wed Feb 14 10:52:30 2024

	Movement Disorders (revue)
	Attention, ce site est en cours de développement ! Attention, site généré par des moyens informatiques à partir de corpus bruts. Les informations ne sont donc pas validées.

Movement Disorders (revue)

Aripiprazole : A Treatment for Severe Coprolalia in "Refractory" Gilles de la Tourette Syndrome

Aripiprazole : A Treatment for Severe Coprolalia in "Refractory" Gilles de la Tourette Syndrome

Source :

Descripteurs français

English descriptors

Abstract

Notice en format standard (ISO 2709)

Format Inist (serveur)

Links to Exploration step

Le document en format XML

Pour manipuler ce document sous Unix (Dilib)

Pour mettre un lien sur cette page dans le réseau Wicri